Bilexa25 mcg+100 mcg

Bilexa is a fixed-dose combination inhaler that is FDA-approved and guideline-supported for the following indications:

• Maintenance treatment of asthma in patients aged 5 years and older whose asthma is not adequately controlled on an inhaled corticosteroid alone, or whose disease severity clearly warrants initiation of combination therapy.
• Maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and for reducing exacerbations of COPD in adults.

Bilexa is a long-term, once-daily maintenance medicine only. It is not a rescue inhaler and is not indicated for the relief of acute bronchospasm or acute asthma/COPD exacerbations; a separate short-acting bronchodilator must be available for acute symptoms.

Vilanterol Trifenatate + Fluticasone Furoate is supplied as a dry powder for oral inhalation, combining two active ingredients in fixed strengths per actuation:

• Vilanterol (as vilanterol trifenatate) - a long-acting beta2-adrenergic agonist (LABA), typically 25 mcg per actuation.
• Fluticasone furoate - an inhaled corticosteroid (ICS), available in strengths such as 50 mcg, 100 mcg, or 200 mcg per actuation depending on the indication and formulation.

The inhaler also contains lactose monohydrate (which contains trace milk proteins) as a carrier excipient. Locally marketed strengths of Vilanterol Trifenatate + Fluticasone Furoate may vary by manufacturer; always check the pack label for the exact strength prescribed.

Bilexa is a fixed-dose combination, multi-dose dry powder inhaler used for the long-term maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It combines vilanterol trifenatate, a long-acting beta2-adrenergic agonist (LABA) that relaxes airway smooth muscle to widen the airways, with fluticasone furoate, an inhaled corticosteroid (ICS) that reduces airway inflammation.

Bilexa is administered as a single inhalation once daily using a breath-activated, multi-dose inhaler device. It is intended for regular, scheduled use to control symptoms and prevent flare-ups, not for immediate relief of sudden breathing difficulty.

Bilexa belongs to the therapeutic class of combination respiratory agents, specifically a fixed-dose combination of a long-acting beta2-adrenergic agonist (LABA) and an inhaled corticosteroid (ICS), used in the management of obstructive airway diseases.

Vilanterol Trifenatate + Fluticasone Furoate works through the complementary actions of its two components:

• Vilanterol selectively stimulates beta2-adrenergic receptors on airway smooth muscle, activating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP). This relaxes bronchial smooth muscle and produces sustained bronchodilation lasting approximately 24 hours, supporting once-daily dosing.
• Fluticasone furoate is a synthetic corticosteroid with high affinity for the glucocorticoid receptor. It suppresses multiple steps of the inflammatory cascade in the airway, including reduced recruitment of inflammatory cells, decreased mediator release, and reduced mucosal edema, thereby reducing airway hyperresponsiveness over time.

Following inhalation, both components are absorbed predominantly through the lungs; systemic exposure is metabolized mainly via the hepatic CYP3A4 pathway. Vilanterol Trifenatate + Fluticasone Furoate is designed for once-daily administration due to the prolonged airway retention and receptor binding of both components.

Bilexa is for oral inhalation only and must never be swallowed, injected, or administered by any other route. It is delivered using a breath-activated, multi-dose dry powder inhaler that does not require priming or shaking. Patients should be trained by a healthcare provider or pharmacist on correct inhaler technique before first use, and should rinse the mouth with water after each dose.

Bilexa has the following well-documented, clinically significant interactions:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin): co-administration with Bilexa can markedly increase systemic exposure to fluticasone furoate and vilanterol, raising the risk of Cushingoid effects, adrenal suppression, and cardiovascular effects (including QT prolongation). Concomitant use should generally be avoided; if unavoidable, monitor closely.
• Non-selective beta-blockers (e.g., propranolol): may block the bronchodilator effect of the vilanterol component of Bilexa and can also produce severe bronchospasm; avoid unless there is a compelling reason, and use cardioselective beta-blockers cautiously if necessary.
• Other adrenergic (sympathomimetic) drugs, including other LABAs: concurrent use with Bilexa may potentiate cardiovascular adverse effects and is not recommended; do not use additional medicines containing a LABA while on Bilexa.
• Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants: may potentiate the cardiovascular effects (e.g., tachycardia, arrhythmia) of the vilanterol component of Bilexa; use with caution.
• Non-potassium-sparing diuretics (loop or thiazide diuretics): may worsen ECG changes and/or hypokalemia associated with beta-agonist therapy; use Bilexa cautiously with these agents.

Common side effects reported with Bilexa include:

• Nasopharyngitis (common cold symptoms)
• Headache
• Upper respiratory tract infection
• Oropharyngeal (oral) candidiasis - thrush
• Hoarseness or voice changes (dysphonia)
• Bronchitis, sinusitis, or pharyngolaryngeal pain
• Back pain and joint pain (arthralgia)
• Influenza

Less common but serious effects that require prompt medical attention include signs of pneumonia (in COPD patients), hypersensitivity reactions (rash, swelling of the face/throat, difficulty breathing), significant changes in heart rate or rhythm, paradoxical bronchospasm (worsening wheeze immediately after use), vision changes, and signs of adrenal suppression. See Precautions and Warnings for further detail on these serious risks.

Pregnancy: There are no adequate and well-controlled studies of Bilexa in pregnant women. Oral corticosteroids and beta-agonists have shown some effects in animal reproduction studies at high systemic exposures. Bilexa should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus; because poorly controlled asthma itself poses risks to both mother and fetus, asthma control should generally be maintained during pregnancy under close physician supervision.

Lactation: It is not known whether the components of Bilexa are excreted in human breast milk in clinically significant amounts. A decision on whether to continue breastfeeding or continue/discontinue therapy with Bilexa should be made in consultation with a physician, weighing the benefits of breastfeeding against the mother's clinical need for the medicine.

The following precautions and warnings apply to Bilexa:

• Boxed Warning (LABA class effect): Long-acting beta2-adrenergic agonists (LABAs), such as the vilanterol component of Bilexa, increase the risk of asthma-related death when used as monotherapy for asthma without an inhaled corticosteroid. Because Bilexa contains an inhaled corticosteroid (fluticasone furoate) in combination with vilanterol, this specific risk is mitigated; however, this class warning is still required labeling for all LABA-containing products, including Bilexa.
• Not for acute symptoms: Bilexa is a maintenance medicine only and must never be used to treat acute bronchospasm or an acute asthma/COPD attack (see Contraindications).
• Local oropharyngeal effects: Oral candidiasis (thrush) and hoarseness can occur with the inhaled corticosteroid component; rinsing the mouth with water after each dose reduces this risk.
• Immunosuppression and infection risk: Inhaled corticosteroids can locally reduce immune defenses; use Bilexa with caution in patients with active or quiescent untreated systemic fungal, bacterial, viral, parasitic, or tuberculous infection, or ocular herpes simplex, as these conditions may worsen.
• Adrenal suppression and hypercorticism: Long-term use of inhaled corticosteroids, especially at higher doses or with strong CYP3A4 inhibitors, can lead to systemic corticosteroid effects, including adrenal insufficiency. Extra caution and monitoring are needed when transferring patients from chronic systemic corticosteroid therapy to Bilexa, as adrenal function may take time to recover; do not stop Bilexa or systemic steroids abruptly.
• Reduced bone mineral density: Long-term use of inhaled corticosteroids in Bilexa may be associated with decreased bone mineral density; consider monitoring in patients with pre-existing risk factors for osteoporosis.
• Growth effects in children: Inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients; growth should be monitored routinely in children using Bilexa.
• Cardiovascular effects: The vilanterol component can produce clinically significant effects on heart rate, blood pressure, and ECG (e.g., QT interval changes); use Bilexa with caution in patients with cardiovascular disorders, particularly coronary insufficiency, arrhythmias, and hypertension.
• Metabolic effects: Beta-agonists such as vilanterol may cause transient hypokalemia or hyperglycemia; use with caution in patients with diabetes or at risk of low potassium.
• Paradoxical bronchospasm: If paradoxical bronchospasm occurs after a dose of Bilexa, discontinue immediately and treat with an alternative fast-acting bronchodilator.
• Hypersensitivity reactions: Anaphylaxis, angioedema, rash, and urticaria have been reported; discontinue Bilexa if a hypersensitivity reaction occurs (see Contraindications regarding milk protein allergy).
• Ocular effects: Long-term inhaled corticosteroid use may increase the risk of glaucoma and cataracts; regular eye examinations are advised with prolonged use of Bilexa.
• Avoid additional LABA use: Patients using Bilexa should not use additional medicines containing a long-acting beta2-agonist.

There is limited clinical experience with overdose of Bilexa. Excessive doses may exaggerate the effects of each component: signs of vilanterol overdose can include tachycardia, palpitations, tremor, headache, muscle cramps, hypokalemia, and hyperglycemia; excessive fluticasone furoate exposure may lead to suppression of the hypothalamic-pituitary-adrenal (HPA) axis with prolonged or high-dose exposure.

If an overdose of Bilexa is suspected, seek immediate medical attention or contact a poison control center right away. There is no specific antidote; management is supportive and symptomatic under medical supervision, with cardiac monitoring where indicated. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep the inhaler in the sealed tray until first use, discard after the labeled number of days once opened or when the dose counter reads zero, and keep out of reach of children.

Hepatic Impairment

Fluticasone furoate is predominantly cleared by the liver; in patients with moderate to severe hepatic impairment, systemic exposure to the corticosteroid component of Bilexa may be increased. Use the lowest effective strength and monitor for systemic corticosteroid effects.

Renal Impairment

No dose adjustment of Bilexa is required in patients with renal impairment.

Elderly (Geriatric Use)

No overall differences in safety or effectiveness of Bilexa have been identified between elderly and younger adult patients, though age-related cardiovascular disease and reduced bone density warrant routine clinical monitoring.

Immunocompromised Patients

Use Bilexa with caution in patients with active untreated infections due to the local immunosuppressive effect of the inhaled corticosteroid component (see Precautions and Warnings).

Bilexa is intended for long-term, regular maintenance treatment of asthma or COPD, not short-term or as-needed use. Physicians should periodically reassess asthma control and consider gradual step-down of therapy once control is well established, or step-up if control is inadequate. In COPD, treatment with Bilexa is generally continued long-term as part of ongoing disease management. Do not stop Bilexa abruptly without physician guidance, particularly after prolonged use.

Vilanterol Trifenatate + Fluticasone Furoate is a fixed-dose combination of two respiratory drug classes: a long-acting beta2-adrenergic agonist (LABA - vilanterol trifenatate) and an inhaled corticosteroid (ICS - fluticasone furoate).

Vilanterol Trifenatate + Fluticasone Furoate combines two complementary mechanisms in the airway: vilanterol trifenatate stimulates beta2-adrenergic receptors on bronchial smooth muscle to produce sustained bronchodilation lasting approximately 24 hours, while fluticasone furoate binds the glucocorticoid receptor to suppress airway inflammation. Together, the components of Vilanterol Trifenatate + Fluticasone Furoate both relieve airflow obstruction and reduce the underlying inflammatory process that drives asthma and COPD exacerbations.

Bilexa is approved for the maintenance treatment of asthma in children aged 5 years and older, using the lowest available strength (vilanterol 25 mcg/fluticasone furoate 50 mcg) as the recommended starting dose in this age group. Safety and efficacy in children younger than 5 years of age have not been established, and Bilexa should not be used in this population. Bilexa is not indicated for the treatment of COPD in pediatric patients, as COPD does not occur in children. Growth velocity should be monitored periodically in pediatric patients receiving long-term treatment with Bilexa, as inhaled corticosteroids may cause a reduction in growth rate.